Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-369M | $-378M | $-301M | -154.0% | - | 53.5% |
| 2024 | $0M | $-238M | $-246M | $-201M | -66.8% | - | 48.6% |
| 2023 | $0M | $-168M | $-166M | $-145M | -73.6% | -100.0% | 23.3% |
| 2022 | $33M | $-131M | $-135M | $-134M | -51.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 33.19 | 0 | 0 | 0 |
| Operating Revenue | - | 33.19 | 0 | 0 | 0 |
| Operating Expense | - | 167.56 | 171.30 | 252.05 | 384.64 |
| Research And Development | - | 124.44 | 121.90 | 184.55 | 208.44 |
| Selling General And Administration | - | 43.12 | 49.40 | 67.50 | 176.20 |
| Total Expenses | - | 167.56 | 171.30 | 252.05 | 384.64 |
| Operating Income | - | -134.37 | -171.30 | -252.05 | -384.64 |
| Total Operating Income As Reported | - | -134.37 | -171.30 | -252.05 | -384.64 |
| EBITDA | - | -131.38 | -168.45 | -237.52 | -369.39 |
| Normalized EBITDA | - | -131.38 | -168.45 | -237.52 | -369.39 |
| EBIT | - | -134.37 | -171.30 | -239.46 | -371.05 |
| Interest Income | - | - | - | 12.68 | 13.90 |
| Interest Expense | - | - | - | 6.84 | 6.89 |
| Net Interest Income | - | - | - | 5.84 | 7.01 |
| Other Non Operating Income Expenses | - | -0.13 | 5.51 | -0.08 | -0.30 |
| Other Income Expense | - | -0.13 | 5.51 | -0.08 | -0.30 |
| Interest Income Non Operating | - | - | - | 12.68 | 13.90 |
| Interest Expense Non Operating | - | - | - | 6.84 | 6.89 |
| Net Non Operating Interest Income Expense | - | - | - | 5.84 | 7.01 |
| Pretax Income | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Net Income From Continuing And Discontinued Operation | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Net Income From Continuing Operation Net Minority Interest | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Net Income | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Net Income Common Stockholders | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Net Income Including Noncontrolling Interests | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Normalized Income | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Diluted NI Availto Com Stockholders | - | -134.50 | -165.79 | -246.29 | -377.94 |
| Basic Average Shares | - | 59.61 | 83.35 | 99.84 | 114.70 |
| Diluted Average Shares | - | 59.61 | 83.35 | 99.84 | 114.70 |
| Reconciled Depreciation | - | 2.99 | 2.84 | 1.94 | 1.66 |
| General And Administrative Expense | - | 43.12 | 49.40 | 67.50 | 176.20 |
| Other Gand A | - | 43.12 | 49.40 | 67.50 | 176.20 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Scholar Rock Holding Corporationthis co. | SRRK | $5.4B | - | 22.13 | -154.0% | - |
| Rhythm Pharmaceuticals, Inc. | RYTM | $6.0B | - | 22.25 | -74.8% | - |
| PACS Group, Inc. | PACS | $5.9B | 30.96 | 6.26 | 20.2% | 24.98 |
| Mirum Pharmaceuticals, Inc. | MIRM | $5.6B | -241.41 | 17.92 | -7.4% | 329.12 |
| Cogent Biosciences, Inc. | COGT |
| - |
| - |
| - |
| - |
| - |
| - |
| $5.6B |
| -17.03 |
| 10.24 |
| -60.1% |
| -17.21 |
| Liquidia Corporation | LQDA | $5.6B | -80.69 | 124.29 | -154.0% | -128.84 |
| CRISPR Therapeutics AG | CRSP | $5.5B | - | 2.86 | -30.3% | - |
| Xenon Pharmaceuticals Inc. | XENE | $5.1B | -14.81 | 8.80 | -59.5% | -13.31 |
| CG Oncology, Inc. | CGON | $4.9B | -30.73 | 6.57 | -21.4% | -26.00 |
| Peer Median | - | -23.88 | 9.52 | -44.9% | -15.26 | |
Historically, Oct has averaged the highest return (+64.1%); Apr the lowest (-17.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.7%Neutral MonthJan 2026: +0.66% | -0.2%Neutral MonthFeb 2026: -0.16% | +11.0%Positive MonthMar 2026: +11.05% | -5.2%Negative MonthApr 2026: -5.19% | +5.8%Positive MonthMay 2026: +5.77% | +11.6%Positive MonthJun 2026: +11.56% | -14.0%Negative MonthJul 2026: -14.01% | +19.5%*Positive MonthAug 2026: +19.48% | — | — | — | — |
| 2025 | -6.6%Negative MonthJan 2025: -6.57% | -3.9%Negative MonthFeb 2025: -3.86% | -17.2%Negative MonthMar 2025: -17.18% | +2.4%Positive MonthApr 2025: +2.36% | -11.9%Negative MonthMay 2025: -11.85% | +22.1%Positive MonthJun 2025: +22.10% | +4.6%Positive MonthJul 2025: +4.60% | -11.9%Negative MonthAug 2025: -11.88% | +14.1%Positive MonthSep 2025: +14.06% | -20.5%Negative MonthOct 2025: -20.46% | +48.8%Positive MonthNov 2025: +48.75% | -0.0%Neutral MonthDec 2025: -0.02% |
| 2024 | -25.8%Negative MonthJan 2024: -25.80% | +11.1%Positive MonthFeb 2024: +11.11% | +14.6%Positive MonthMar 2024: +14.58% | -17.4%Negative MonthApr 2024: -17.40% | -36.0%Negative MonthMay 2024: -35.99% | -11.3%Negative MonthJun 2024: -11.29% | +9.0%Positive MonthJul 2024: +9.00% | +2.4%Positive MonthAug 2024: +2.42% | -13.9%Negative MonthSep 2024: -13.87% | +255.1%Positive MonthOct 2024: +255.06% | +40.3%Positive MonthNov 2024: +40.30% | +8.3%Positive MonthDec 2024: +8.32% |
| 2023 | +33.7%Positive MonthJan 2023: +33.70% | -29.1%Negative MonthFeb 2023: -29.09% | -6.8%Negative MonthMar 2023: -6.76% | -20.0%Negative MonthApr 2023: -20.00% | -9.1%Negative MonthMay 2023: -9.06% | +29.6%Positive MonthJun 2023: +29.55% | -5.8%Negative MonthJul 2023: -5.84% | -12.0%Negative MonthAug 2023: -11.97% | +13.6%Positive MonthSep 2023: +13.60% | +65.6%Positive MonthOct 2023: +65.63% | +7.1%Positive MonthNov 2023: +7.06% | +49.3%Positive MonthDec 2023: +49.32% |
| 2022 | -28.3%Negative MonthJan 2022: -28.30% | -2.3%Negative MonthFeb 2022: -2.30% | -25.9%Negative MonthMar 2022: -25.92% | -45.2%Negative MonthApr 2022: -45.15% | -29.0%Negative MonthMay 2022: -29.00% | +9.4%Positive MonthJun 2022: +9.36% | +25.0%Positive MonthJul 2022: +24.95% | +21.6%Positive MonthAug 2022: +21.57% | -16.9%Negative MonthSep 2022: -16.91% | +40.8%Positive MonthOct 2022: +40.84% | -20.4%Negative MonthNov 2022: -20.39% | +16.5%Positive MonthDec 2022: +16.47% |
| 2021 | — | — | — | — | -16.9%Negative MonthMay 2021: -16.94% | +7.6%Positive MonthJun 2021: +7.55% | +8.1%Positive MonthJul 2021: +8.13% | +26.5%Positive MonthAug 2021: +26.50% | -16.5%Negative MonthSep 2021: -16.47% | -20.4%Negative MonthOct 2021: -20.35% | +1.0%Neutral MonthNov 2021: +0.95% | -6.4%Negative MonthDec 2021: -6.44% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
